SUBSCRIBE
SUBSCRIBE

Phase III

Pictured: Exelixis headquarters/Company courtesy
Drug Development
Exelixis Shoots Up as Cancer Drug Meets Goals in Phase III Trial
Cabometyx hit key endpoints of overall survival in its Phase III liver cancer trial and investors are overjoyed.
October 16, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
Questions Arise Over Ionis and Its New Phase III ATTR Study Data
Ionis Pharma released new data from its Phase III NEURO-TTR trial with inotersen in patients with hereditary TTR amyloidosis with polyneuropathy.
October 15, 2017
 · 
2 min read
 · 
Mark Terry
Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
Eli Lilly Dealt Another Setback as Lung Cancer Drug Flunks Phase III Test
Drug Development
Eli Lilly Dealt Another Setback as Lung Cancer Drug Flunks Phase III Test
October 10, 2017
 · 
2 min read
Drug Development
Biogen’s Alzheimer’s Pipeline Gets Some More Love
October 6, 2017
 · 
1 min read
Bayer Halts Phase III Study on New Xarelto Indication
Drug Development
Bayer Halts Phase III Study on New Xarelto Indication
October 6, 2017
 · 
2 min read
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Drug Development
Despite One Death and One Adverse Event, bluebird bio’s Gene Therapy Study Meets Goals
October 5, 2017
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Acadia Scraps a Phase II Alzheimer’s Trial, Gets Breakthrough Tag for Dementia-Related Drug
October 5, 2017
 · 
3 min read
Why This Biotech, Up 300% Since May, Could be the Next Big M&A Target
Drug Development
Motif Bio Explodes After Phase III Clinical Trial Success
October 4, 2017
 · 
2 min read
Why This Biotech, Up 300% Since May, Could be the Next Big M&A Target
Drug Development
Bay Area’s Zogenix Explodes on Late-Stage Epilepsy Data
September 29, 2017
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Press Releases
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
January 28, 2026
 · 
4 min read
Press Releases
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
January 28, 2026
 · 
7 min read
Press Releases
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
January 28, 2026
 · 
6 min read
Press Releases
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
January 27, 2026
 · 
16 min read
Press Releases
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
January 26, 2026
 · 
4 min read
Press Releases
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
January 26, 2026
 · 
3 min read
Press Releases
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 23, 2026
 · 
17 min read
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
 · 
7 min read
Press Releases
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 22, 2026
 · 
17 min read
Press Releases
IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia
January 21, 2026
 · 
5 min read
Load More